Roberto A. Mignone Joins Guardant Health Board of Directors
Guardant Health (Nasdaq: GH) announced the appointment of Roberto A. Mignone to its board of directors. Mignone, the Founder and Managing Partner of Bridger Management , brings healthcare industry expertise and business strategy experience to the company. He currently serves as co-Vice Chairman at NYU Langone Medical Center and board member at Teva Pharmaceuticals. The appointment follows Guardant Health's FDA approval of Shield, its early-stage colorectal cancer screening product.
Guardant Health (Nasdaq: GH) ha annunciato la nomina di Roberto A. Mignone nel proprio consiglio di amministrazione. Mignone, Fondatore e Managing Partner di Bridger Management, porta con sé competenze nell'industria della salute e esperienza nella strategia aziendale. Attualmente ricopre il ruolo di co-Vice Presidente presso il NYU Langone Medical Center ed è membro del consiglio di amministrazione di Teva Pharmaceuticals. Questa nomina arriva dopo l'approvazione da parte della FDA del prodotto Shield di Guardant Health, per lo screening precoce del cancro colorettale.
Guardant Health (Nasdaq: GH) anunció el nombramiento de Roberto A. Mignone en su consejo de administración. Mignone, fundador y socio gerente de Bridger Management, aporta experiencia en la industria de la salud y en estrategia empresarial a la compañía. Actualmente se desempeña como co-Vicepresidente en el NYU Langone Medical Center y es miembro del consejo de Teva Pharmaceuticals. El nombramiento sigue a la aprobación por parte de la FDA de Shield, su producto para la detección temprana del cáncer colorrectal.
가드란트 헬스 (Nasdaq: GH)는 로베르토 A. 미뇨네를 이사회에 임명했다고 발표했습니다. 미뇨네는 브리저 매니지먼트의 창립자이자 관리 파트너로서 헬스케어 산업에 대한 전문지식과 비즈니스 전략 경험을 회사에 제공하고 있습니다. 그는 현재 NYU 랭곤 의료센터의 공동 부회장으로 재직 중이며, 테바 제약의 이사회위원이기도 합니다. 이번 임명은 가드란트 헬스의 조기 대장암 검진 제품인 Shield가 FDA 승인을 받은 것에 따른 것입니다.
Guardant Health (Nasdaq: GH) a annoncé la nomination de Roberto A. Mignone au sein de son conseil d'administration. Mignone, fondateur et partenaire gérant de Bridger Management, apporte son expertise dans l'industrie de la santé et son expérience en stratégie d'entreprise à la société. Il est actuellement co-Vice-président au NYU Langone Medical Center et membre du conseil d'administration de Teva Pharmaceuticals. Cette nomination fait suite à l'approbation par la FDA de Shield, son produit de dépistage précoce du cancer colorectal.
Guardant Health (Nasdaq: GH) gab die Ernennung von Roberto A. Mignone in seinen Vorstand bekannt. Mignone, der Gründer und Managing Partner von Bridger Management, bringt Fachkenntnisse aus der Gesundheitsindustrie und Erfahrung in der Unternehmensstrategie ein. Derzeit ist er Co-Vorsitzender am NYU Langone Medical Center und Vorstandsmitglied bei Teva Pharmaceuticals. Die Ernennung folgt auf die FDA-Zulassung von Shield, einem Produkt zur Früherkennung von Dickdarmkrebs, von Guardant Health.
- Strategic board addition with extensive healthcare investment expertise
- Appointment follows recent FDA approval of Shield cancer screening product
- None.
“We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “We look forward to Mr. Mignone’s perspective as we strengthen our product offerings across the continuum of care, and look forward to the long-term impact this can have on patients.”
Since its founding in 2020, Bridger Management has expanded its focus on the healthcare sector, in addition to its investments across global consumer, technology, and financial service companies. With his appointment, Mr. Mignone will bring his vast experience and expertise in business strategy to Guardant Health, following the FDA approval of its early-stage colorectal cancer screening product, Shield.
“I continue to be inspired by companies like Guardant Health that find new, innovative ways to solve some of the world’s most pressing challenges,” said Mr. Mignone. “Through Guardant Health, we have the potential to provide better care to cancer patients globally, which is a mission I look forward to contributing to.”
Prior to Bridger Management, Mr. Mignone co-founded Blue Ridge Capital LLC, an investment firm that focused on healthcare, technology, media, telecommunications, and financial services investing. He currently serves as the co-Vice Chairman at the New York University Langone Medical Center. He is also a member of the board at Teva Pharmaceuticals.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024606035/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
Source: Guardant Health, Inc.
FAQ
Who is Roberto Mignone joining Guardant Health (GH) board?
What is Roberto Mignone's experience before joining Guardant Health (GH)?
What recent milestone did Guardant Health (GH) achieve before Mignone's appointment?
